- Home
- RANI vs NXL Comparison
RANI vs NXL Comparison
Compare RANI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RANI
- NXL
- Stock Information
- Founded
- RANI 2012
- NXL 2010
- Country
- RANI United States
- NXL United States
- Employees
- RANI N/A
- NXL N/A
- Industry
- RANI Medicinal Chemicals and Botanical Products
- NXL Medical Specialities
- Sector
- RANI Health Care
- NXL Health Care
- Exchange
- RANI Nasdaq
- NXL Nasdaq
- Market Cap
- RANI 24.2M
- NXL 25.1M
- IPO Year
- RANI 2021
- NXL 2022
- Fundamental
- Price
- RANI $1.90
- NXL $1.08
- Analyst Decision
- RANI Strong Buy
- NXL Strong Buy
- Analyst Count
- RANI 6
- NXL 1
- Target Price
- RANI $8.67
- NXL $5.00
- AVG Volume (30 Days)
- RANI 21.6M
- NXL 389.1K
- Earning Date
- RANI 11-06-2025
- NXL 11-07-2025
- Dividend Yield
- RANI N/A
- NXL N/A
- EPS Growth
- RANI N/A
- NXL N/A
- EPS
- RANI N/A
- NXL N/A
- Revenue
- RANI $1,200,000.00
- NXL $156,931.00
- Revenue This Year
- RANI N/A
- NXL $38.28
- Revenue Next Year
- RANI N/A
- NXL $185.71
- P/E Ratio
- RANI N/A
- NXL N/A
- Revenue Growth
- RANI N/A
- NXL 16.42
- 52 Week Low
- RANI $0.39
- NXL $0.70
- 52 Week High
- RANI $3.87
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- RANI 54.20
- NXL 38.01
- Support Level
- RANI $1.77
- NXL $1.03
- Resistance Level
- RANI $2.16
- NXL $1.31
- Average True Range (ATR)
- RANI 0.35
- NXL 0.12
- MACD
- RANI -0.07
- NXL -0.06
- Stochastic Oscillator
- RANI 41.74
- NXL 6.13
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.